Close Menu

Enzo

The flow cytometry-based test is the first available for the firm's FlowScript platform and allows for the simultaneous analysis of multiple genes expressed in a single cell.

NEW YORK (GenomeWeb) – Enzo Biochem said on Thursday that revenues in its fiscal fourth quarter rose 7 percent year over year.

NEW YORK (GenomeWeb) – Enzo Biochem today said that PerkinElmer will pay the firm $7 million as part of a legal settlement reached between the firms last week.

NEW YORK (GenomeWeb) – Enzo Biochem said on Monday that its revenues for its fiscal third quarter were up 6 percent year over year.

NEW YORK (GenomeWeb) – Affymetrix will pay $5.1 million to settle two decade-old cases with Enzo Biochem, Enzo said today.

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market Tuesday that its second quarter revenues increased 3 percent year over year, with growth posted for both its life sciences products and clinical lab services.

NEW YORK (GenomeWeb News) – Enzo Clinical Labs and Nuclea Biotechnologies have entered into an agreement to market Nuclea's non-invasive HER-2/neu serum test for monitoring metastatic breast cancer, Enzo Biochem announced today.

NEW YORK (GenomeWeb News) – Enzo Biochem today said that a federal court has awarded the firm an additional $12.4 million in prejudgment interest in connection with a November 2012 jury verdict which found that Life Technologies infringed Enzo's patents.

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market yesterday a 6 percent drop in its FY 2014 revenues year over year.

NEW YORK (GenomeWeb News) – Enzo Biochem today said that it has signed an agreement to market Sequenom's MaterniT21 Plus test service in the northeast US.

Pages

Bloomberg reports that vaccine developers won't have to conduct large trials of updated vaccines or vaccine boosters aimed at new viral variants.

The SARS-CoV-2 variant uncovered in California may be more transmissible and partially evade vaccine-induced antibody response, the Los Angeles Times reports.

Francis deSouza, the CEO of Illumina, calls for a global SARS-CoV-2 genomics surveillance network, according to the Financial Times.

In PNAS this week: immunotherapy for hard-to-treat breast cancers, effects of oncogenic histone H3K36M mutations, and more.